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ABSTRACT 
 
When liver cells gets infected and vandalized, the condition is termed as Hepatitis. HCV therapy is performed 
with mixture of drugs. For the combined evaluation of Pibrentasvir and Glecaprevir in tablets, a rapid, se-
lective and robust HPLC technique stability indicating was developed herein this work. Analysis was exe-
cuted by Cosmicsil, with dimensions 250 mm by 4.6 mm column and mobile phase possessing KH2PO4 with 
0.1M, 65 ml and 35 ml of methanol and 230 nm of PDA analysis. Elution times were found out as were 1.663 
min and 2.249 min, for Pibrentasvir and Glecaprevir respectively with linear ranges 20µg/ml, 60 µg/ml and 
50 µg/ml, 150 µg/ml, respectively having detection limits as 0.190 µg/ml and 0.207  µg/ml and quantization 
limits as 0.634 µg/ml and 0.690 µg/ml. This method is explicit having RSD values as 0.097% Pibrentasir & 
0.232% Glecaprevir showing an accuracy of between 98.82 and 100.07% for Pibrentasir 99.31, Glecaprevir 
100.45% recovery values. During the investigation of degradation, peaks elution times of degradants greatly 
varied with the elution times of Glecaprevir and Pibrentasvir thus, proving method‘s power of stability in-
dication and specificity. The validation and degradation stability studies were carried out according to ICH 
and ICH Q1B Guidelines.  
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INTRODUCTION 
When liver cells gets infected and vandalized, the 
condition is termed as Hepatitis. Although there are 
varied reasons for its occurrence and types, similar 
symptoms may be exhibited [1]. The major service of 
liver is to detoxify blood, store vitamins and manufac-
ture hormones. Disruption of previously stated liver 
functions may lead to severe health issues in total 
body [2]. The acute and major kinds are Hepatitis A, B, 
C caused because of various viruses [3, 4].. Multi-class 
combination drugs refer to a single pill or pill pack 
combination of drugs. The combination of used drugs 
approved is represented in (Table 1). Pibrentasvir 
acts on NS3A proteases are indispensable to replica-
tion of hepatitis C virus RNA and virus assembly. 
These processes are clogged and hence virus growth 
is held in by Pibrentasvir [5-7]. Glecaprevir Proteases 
NS4A and 5A are preconditions for RNA replication 
and virus assembly of hepatitis C virus. Hence, blocks 
these two processes and thus virus development is 
suppressed [8-10].  
 
Figure 1: Structure of Pibrentasvir 
 
Figure 2: Structure of Glecaprevir 
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To the finest of our information, handful studies use 
HPLC and UPLC to assess pibrentasvir together with 
glecaprevir [11-17].  
The main aim of this investigation is an effort to es-
tablish the RP-HPLC method which is stability indi-
cating for testing pibrentasvir and glecaprevir which 
is economically friendly, fast and have a wide accu-
rate range. The established method is validated for 
parameters such as sensitivity, linearity, specificity, 
selectivity, accuracy, robustness and precision ac-
cording to ICH Guidelines [18]. And degradation stud-
ies were carried out to represent the method sensi-
tivity according to ICH Q1B Guidelines [19].  
MATERIALS AND METHODS 
Materials used: The materials employed were Pi-
brentasvir, Glecaprevir, Methanol, Hydrochloric acid, 
Sodium hydroxide, Hydrogen peroxide, and Potas-
sium dihydrogen phosphate.  
The apparatus used were Waters alliance HPLC sys-
tem, Photodiode array detector and Cosmicsil analyt-
ical column, measuring C18, 250 x4. 6 mm, 5 µm 
HPLC technique conditions: The Mobile phase flow 
rate was 1.0ml/Min, Temperature was maintained at 
25˚C, Volume subjected was 10µl, Run time was 5min, 
detected at the wave length of 230nm and maintained 
pH was 4.5.  
Preparation of mobile phase 
KH2PO4 of 0.1 M is blended in 65:35 parts with meth-
anol: Orthophosphoric acid is used to alter pH to 4.5. 
This mixture is also applied as a solvent in the devel-
opment of standard solutions.  
Preparation of stock solution 
Implicated in the preparation of stock solution of pi-
brentasvir and glecaprevir, a properly weighed 40 mg 
pibrentasvir and 100 mg glecaprevir in a 100 ml vol-
umetric flask and exactly diluted with mobile phase. 
Concentration of stock solutions: pibrentasvir 400 
μg/ml and glecaprevir 1000 μg/ml.  
Preparation of sample solutions for validation 
The standard solution to validate pibrentasvir and 
glecaprevir was performed in which mobile phase 
was used to dilute one ml of stock of pibrentasvir and 
glecaprevir to ten ml in the flask of capacity 10 ml. 
Standard solution concentration for validation is pi-
brentasvir 40 µg/ml and glecaprevir 100 µg/ml.  
Optimized method 
After several trials a method was optimized with fol-
lowing conditions represented in (Table 2) and re-
sults are represented in (Figure 3).  
Assay of Pibrentasvir and Glecaprevir in Maviret 
tablet 
Involved in the preparation of pibrentasvir and 
glecaprevir stock tablet solution, a properly weighed 
finely powdered Marivet tablet equivalent to 40 mg 
pibrentasvir and 100 mg glecaprevir in a 100 ml vol-
umetric flask with 30 ml mobile phase were mixed. 
Concentrations of stock tablet solutions are 
400µg/ml and 1000 µg/ml of pibrentasvir & 
glecaprevir respectively. Test tablet solution concen-
trations are 40µg/ml (pibrentasvir) and 100 µg/ml 
(glecaprevir).  
A sample solution amounting 20 μl was 3 times in-
fused into HPLC. The peak areas are measured at 230 
nm and concentrations of pibrentasvir and 
glecaprevir in tablet specimens were determined 
with the help of linear regression equation or calibra-
tion graphs.  
 
Figure 3: Linearity curves of Pibrentasvir and 
Glecaprevir 
RESULTS AND DISCUSSIONS 
A stability indicating method development & valida-
tion of Pibrentasvir and Glecaprevir was done by RP-
HPLC method. The estimation was done by the analy-
sis in RP-HPLC employing Cosmicsil C18 (250×4. 
6mm, 5µm) chromatographic column. The mobile 
phase was mixture of Phosphate Buffer and Acetoni-
trile (65:35). The flow rate was 1.0 ml/ min and de-
tection was performed at 230 nm.  
Validation 
The new technique has been assessed to meet the In-
ternational Conference on Harmonization (ICH) Q1B 
criteria, including sensitivity, linearity, selectivity, ac-
curacy, specificity, robustness and precision.  
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Table 1: Multi-class drug combination to treat Hepatitis C virus 
Brand Name Generic Name Status Pharmaceutical Company 
Epclusa* Sofosbuvir + Velpatasvir Approved Gilead Sciences 
Harvoni* Ledipasvir + Sofosbuvir Approved Gilead Sciences 
Mavyret Glecaprevir + Pibrentasvir Approved Abbvie 
Vosevi Sofosbuvir/Velpatasvir/ Voxilaprevir Approved Gilead Sciences 
Zepatier Elbasvir + Grazoprevir Approved Merck 
n/a Dactlatasvir + Asunaprevir + Beclabuvir Phase III Bristol-Myers Squibb 
Table 2: Optimized method conditions 
Combo and ratio in blend of mobile phase KH2PO4 (65%) and Acetonitrile (35%) 
Trial Column C18 Cosmicsil, 250 mm × 4.6 mm, 5 µm particle dimension 
Flow rate trial 1.0 ml/min 
Size of vol. sample injected 10 µl 
Column temperature trial 25oC 
Time run 5 min 
Eluents checked at 230 nm 
 
Figure 4: Chromatogram of optimized method 
 
Figure 5: Chromatograms of selectivity 
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Selectivity 
The selectivity evaluation was conducted by incorpo-
rating into the chromatographic system a volume of 
20 μg solution standard (40 μg/ml pibrentasvir and 
100 μg/ml glecaprevir), tablet sample (40 μg/ml pi-
brentasvir and 100 μg/ml glecaprevir) blank diluent 
and placebo. No peaks that interfere with peaks when 
pibrentasvir and glecaprevir are retained. These re-
sults are represented in (Figure 4).  
Linearity 
Linearity solutions were prepared with concentra-
tions pibrentasvir and glecaprevir each solution for 
concentration was incorporated into the HPLC in-
strument and assessed according to the similar con-
ditions. The results are represented in (Table 3) and 
linearity graphs are shown in (Figure 5).  
Table 3: Peak area and concentration data 
Conc of 
Glecaprevir 
µg/ml 
Glecaprevir 
Area re-
sponse 
Conc of  
Pibrentasvir 
µg/ml 
Pibren-
tasvir 
Area re-
sponse 
50 1353890 20 469419 
75 2038068 30 704724 
100 2712858 40 939681 
125 3392084 50 1171910 
150 4073013 60 1408097 
The linearity range of Pibrentasvir was found to be 
HPLC 20-60 µg/ml, with R2 value of 0.9995 and line-
arity range of Glecaprevir was found to be HPLC 60-
150 µg/ml, with R2 value of 0.9997. The %RSD for  in-
tra precision was <2%. The % recovery varies in the 
range of 95-105. The method also passes the specifi-
cations for robustness parameters 
Sensitivity 
The sensitivity measurement (LOD and LOQ) is per-
formed by the signal to noise (S/N) ratio for both the 
drugs. Values proved good sensitivity. Results are 
represented in (Figure 6). LOD and LOQ was calcu-
lated by using following formula 
LOD: 
 3.3
𝑆𝐷
× 100, LOQ: 
10
𝑆𝐷
× 100 
LOD: 0.190 µg/ml for Pibrentasvir and 0.20 µg/ml for 
Glecaprevir. LOQ: 0.634 µg/ml for Pibrentasvir and 
0.690 µg/ml for Glecaprevir. 
Precision 
For precise measurement six area response measure-
ments of standard solution (40 μg/ml pibrentasvir 
and 100 μg/ml glecaprevir) were used. The RSD was 
calculated and it was precise.  
Table 4: Area response of Glecaprevir and Pibren-
tasvir for precision 
Area response Area response 
Glecaprevir Pibrentasvir 
Sample I 2708652 939412 
Sample II 2716419 938701 
Sample III 2705033 939606 
Sample IV 2714205 938661 
Sample V 2700375 937041 
Sample VI 2714368 938340 
Average 2709842 938627 
Standard Deviation 6276.050414 914.2279 
RSD 0.232 0.097 
Accuracy 
The precision was evaluated using tablets by pibren-
tasvir and glecaprevir recovery research. Each level 
concentration was prepared and analyzed for three 
times. For replicate specimens, the recovery percent-
age of added analytes was calculated. The result re-
vealed the accuracy.  
Robustness 
Robustness was evaluated by inspecting the impacts 
in assay circumstances generated by minor alterna-
tions. The Theoretical plate count, asymmetry factor, 
resolution of analytes and peak area of glecaprevir 
and pibrentasvir in every condition shows that there 
was no major changes observed. Hence, the method 
is robust.  
Degradation Studies for Pibrentasvir and 
Glecaprevir 
Acid Hydrolysis - Degrading With 0.1n Hcl 
10 ml solution of tablet with 400 µg/ml concentration 
of Pibrentasvir and 1000 µg/ml concentration of 
Glecaprevir was blended to 10 ml of Hcl with normal-
ity 0.1N at 27oC up to 30 min by sonication.  
Base hydrolysis degrading with 0.1N NaOH 
10 ml tablet solution (strength of 400 μg / ml pibren-
tasvir and 1000 μg / ml glecaprevir) was combined at 
27oC to 10 ml 0.1N NaOH for 30 min by sonication.  
Oxidative hydrolysis degrading with 30% hydro-
gen peroxide 
10 ml of tablet solution (concentration of 400 μg/ml 
pibrentasvir and 1000 μg/ml glecaprevir) was com-
bined for 1/2 an hour with 10 ml 30 percent H2O2 at 
27oC through sonication.  
Thermal analysis degrading with dry heat at 
105oC 
Tablet solution at temperature of 1050C (concentra-
tion 400μg/ml pibrentasvir and 1000 μg/ml 
glecaprevir) is applied for 30 min to 10 ml in hot air 
oven.  
Photolysis Degrading with sunlight 
10 ml tablet solution (400 μg/ml pibrentasvir con-
centration and 1000 μg/ml glecaprevir concentra-
tion) is held in sunlight for 6 hours.  
Pibrentasvir and glecaprevir was more degraded in 
dry heat condition and less degraded in peroxide con-
dition. The peak elution times of the degradants are  
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Figure 6: Sensitivity test chromatograms 
Table 5: Recovery data for Pibrentasvir for accuracy 
Level 
Area of response 
Pibrentasvir 
Conc. of Pibrentasvir 
added (µg/ml) 
Conc. of Pibrentasvir 
found (µg/ml) 
Percentage of Pibrentasvir 
Recovered 
50% spiked 
 
468954 19.8 19.78 99.89 
468666 19.8 19.77 99.83 
469413 19.8 19.80 99.99 
100% spiked 
 
938544 39.6 39.58 99.96 
938907 39.6 39.60 99.99 
939645 39.6 39.63 100.07 
150% spiked 
 
1397221 59.4 58.93 99.20 
1391781 59.4 58.70 98.82 
1400703 59.4 59.07 99.45 
Table 6: Recovery data for Gecaprevir for accuracy 
Level 
Area of response 
Glecaprevir 
Conc. of Glecaprevir 
added (µg/ml) 
Conc. of Glecaprevir 
found (µg/ml) 
Percentage of Glecaprevir 
Recovered 
50% spiked 
 
1343575 49.5 49.16 99.31 
1350505 49.5 49.41 99.82 
1341895 49.5 49.10 99.18 
100% spiked 
 
2703946 99.0 98.93 99.93 
2710263 99.0 99.16 100.16 
2701147 99.0 98.83 99.83 
150% spiked 
 
4066263 148.5 148.77 100.18 
4068818 148.5 148.87 100.25 
4076857 148.5 149.16 100.45 
Table 7: Robustness data of Pibrentasvir 
Sample Name Peak Name RT Area USP Tailing USP Plate Count 
FLOW-1 Pibrentasvir 1.376 787370 1.38 4713 
FLOW-2 Pibrentasvir 1.499 859477 1.39 4946 
TEMP-1 Pibrentasvir 1.823 1059372 1.40 5582 
TEMP-2 Pibrentasvir 2.054 1191705 1.40 5973 
COMP-1 Pibrentasvir 1.376 787370 1.38 4713 
COMP-2 Pibrentasvir 1.823 1059372 1.40 5582 
pH-1 Pibrentasvir 1.657 942412 1.38 4997 
pH-2 Pibrentasvir 1.654 939701 1.37 4973 
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distinct from the time of glecaprevir and pibrentasvir 
being eluted. So interference will not occur. Results 
proved stability indicating ability.  
CONCLUSION 
Stability study on Pibrentasvir and Glecaprevir was 
carried out was an efficient HPLC method for the 
quantification of Pibrentasvir and Glecaprevir and 
identification of its degradation products and vali-
dated. The results of stress testing of API, undertaken 
to the ICH Q1B guidelines, revealed that degradation 
products were formed under acidic, alkaline, oxidiz-
ing and thermal conditions.  
The results show the method is accurate, precise, sen-
sitive, and economic friendly and rapid. Hence, the 
method can be successfully applied to the pharma-
ceutical dosage form and can be used for routine anal-
ysis.  
ACKNOWLEDGEMENT 
I am thankful to P. Rami Reddy Memorial College of 
pharmacy to provide facilities to carry out Research 
work.  
ACKNOWLEDGEMENTS 
Nutech Biosciences Pvt Ltd, for providing the gift 
samples of Amlodipine and Lisinopril and also to 
Seven Hills College of Pharmacy for providing facili-
ties to carry out the research work.  
REFERENCES 
1. Hepatitis. Medline plus. U. S. National Library of 
Medicine, accessed on April 2019. Available at: 
https://medlineplus. gov/hepatitis. html  
2. Colli, A., Berzuini, A., & Prati, D. (2018). Liver se-
questration in sickle-cell disease and hepatitis. 
The Lancet, 392(10164), e16.  
3. Center for Substance Abuse Treatment. (1995). 
Treatment Improvement Protocol (TIP) Series, No 
22.LAAM in the treatment of opiate addiction. 
Rockville, MD: Department of Health and Human 
Services.  
4. Gilson R, Brook MG. Hepatitis A, B, and C. Sexually 
Transmitted Infections, 2006, 82 (Supple 4), iv35-
iv39.  
5. Pibrentasavir. Pubchem, U. S. National Library of 
Medicine. Accessed on April 2019, Available at : 
https://pubchem. ncbi. nlm. nih. gov/com-
pound/Pibrentasvir  
6. Pibrentasavir. Drug bank. Accessed on April 2019, 
Available at: https://www. drugbank. 
ca/drugs/DB13878  
7. Ng, T. I., Krishnan, P., Pilot-Matias, T., Kati, W., 
Schnell, G., Beyer, J.,.. & Tripathi, R. (2017). In vitro 
antiviral activity and resistance profile of the 
next-generation hepatitis C virus NS5A inhibitor 
pibrentasvir. Antimicrobial agents and chemo-
therapy, 61(5).  
8.  Glecaprevir. Pubchem, U. S. National Library of 
Medicine. Accessed on April 2019, Available at : 
https://pubchem. ncbi. nlm. nih. gov/com-
pound/Glecaprevir  
9. Glecaprevir. Drug bank. Accessed on April 2019, 
Available at : https://www. drugbank. 
ca/drugs/DB13879  
10. Lawitz, E. J., O'Riordan, W. D., Asatryan, A., 
Freilich, B. L., Box, T. D., Overcash, J. S.,... & Lin, C. 
W. (2016). Potent antiviral activities of the direct-
acting antivirals ABT-493 and ABT-530 with 
three-day monotherapy for hepatitis C virus gen-
otype 1 infection. Antimicrobial agents and chem-
otherapy, 60(3), 1546-1555.  
Table 8: Robustness data of Glecaprevir 
Sample Name Peak Name RT Area USP Tailing USP Plate Count USP Resolution 
FLOW-1 Glecaprevir 1.847 2291831 1.29 5379 5.06 
FLOW-2 Glecaprevir 2.007 2506019 1.29 5551 5.12 
TEMP-1 Glecaprevir 2.429 3070004 1.29 6110 5.30 
TEMP-2 Glecaprevir 2.751 3463366 1.30 6742 5.63 
COMP-1 Glecaprevir 1.847 2291831 1.29 5379 5.06 
COMP-2 Glecaprevir 2.429 3070004 1.29 6110 5.30 
pH-1 Glecaprevir 2.233 2718652 1.27 5782 5.30 
pH-2 Glecaprevir 2.230 2716419 1.27 5703 5.28 
Table 9: Data achieved for degradation study 
Test 
Pibrentasvir Glecaprevir 
Area 
Response 
Percentage 
remained 
Percentage  
degraded 
Area 
Response 
Percentage 
remained 
Percentage  
degraded 
Acid 857202 90.38 9.62 2505748 91.68 8.32 
Alkali 906340 95.56 4.44 2594536 94.93 5.07 
H2O2 914387 96.41 3.59 2646545 96.83 3.17 
Dry heat 845426 89.14 10.86 2403035 87.92 12.08 
Sun light 904050 95.32 4.68 2555828 93.51 6.49 
 
 Patta Salomi et al., (2020) Int. J. Res. Pharm. Chem & Analy., 1(4), 88-94 
94   © Rubatosis Publications | International Journal of Research in Pharmaceutical Chemistry and Analysis 
 
11. Hemalatha, K., Kistayya, C., Nizamuddhin, N. D., & 
Dastiagiriamma, D. (2018). Simultaneous estima-
tion of new analytical method development and 
validation of glecaprevir and pibrentasvir by high 
performance liquid chromatography. Innovat In-
ternational Journal Of Medical & Pharmaceutical 
Sciences, 3(7).  
12. Babu, D., Chetty, C. M., & Mastanamma, S. K. 
(2018). A New Force Indicating RP-HPLC Method 
Development and Validation for the Simultaneous 
Estimation of Pibrentasvir and Glecaprevir in Bulk 
and its Tablet Dosage Form. Pharmaceutical Meth-
ods, 9(2).  
13. Sreeram, V., & Venkateswarlu, C. (2018). Stability 
indicating RP-HPLC method for the simultaneous 
estimation of glecaprevir and pibrentasvir in drug 
product. Journal of pharmaceutical sciences and 
research, 10(11), 2757-2761. 
14. Rama Kumar, K., & Raja, S. (2018). Simultaneous 
assay of two antiviral agents, Pibrentasvir and 
Glecaprevir, using stability indicating RP-HPLC 
method in bulk and tablets. Der Pharmacia Letter, 
10(8), 33-47.  
15. Gampa VK, Reddy DS. (2018) RP- HPLC method 
development and validation for simultaneous es-
timation of glecaprevirand pibrentasvir in phar-
maceutical dosage form. Indo american journal of 
Pharmaceutical sciences, 05 (12), 16827-16840. 
16. Saroja, J., Lakshmi, P. A., Ram Mohan, Y., & Divya, 
D. (2019). Quantification of antiviral drug combi-
nation, Glecaprevir and Pibrentasvir, in bulk and 
tablet formulation by stability indicating RP-HPLC 
method. The Pharma Innovation Journal, 8(1), 
163-169.  
17.  Marakada S, Rao TS, Challa GN. (2018) Develop-
ment and validation for the simultaneous estima-
tion of glecaprevir and pibrentasavir in drug 
product by UPLC. European Journal of Biomedical 
and Pharmaceutical Sciences, 5 (4), 473-480. 
18. ICH, (2006), Harmonized Tripartite Guideline, 
Validation of Analytical procedure: Text and 
Methodology, Geneva, Switzerland.  
19. ICH, (Q1B), (1996), Harmonized Tripartite Guide-
line, Stability testing: Photo stability testing of 
New Drug Substances and Products, in: Proceed-
ing of the International Conference on Harmoni-
zation, Geneva.  
